Bharat Biotech's Covaxin shows over 77% efficacy in phase 3 trials

Bharat Biotech’s Covaxin, India’s first indigenous vaccine against Covid-19, has shown 77.6 per cent efficacy in the final analysis of phase 3 clinical trials, according to sources in the expert panel that reviewed the data.

The vaccine has shown an efficacy rate of 93 per cent against severe disease and 60 per cent against asymptomatic Covid-19.

The Hyderabad-based vaccine manufacturer sought a full marketing authorisation for Covaxin after presenting the final analysis of phase 3 data before the Subject Expert Committee (SEC), which is advising the Drugs Controller General of India (DCGI), a source said.

“A full marketing authorisation has not yet been